MX2023007116A - Composiciones y metodos para modular la expresion de myc. - Google Patents

Composiciones y metodos para modular la expresion de myc.

Info

Publication number
MX2023007116A
MX2023007116A MX2023007116A MX2023007116A MX2023007116A MX 2023007116 A MX2023007116 A MX 2023007116A MX 2023007116 A MX2023007116 A MX 2023007116A MX 2023007116 A MX2023007116 A MX 2023007116A MX 2023007116 A MX2023007116 A MX 2023007116A
Authority
MX
Mexico
Prior art keywords
compositions
expression
methods
modulation
myc expression
Prior art date
Application number
MX2023007116A
Other languages
English (en)
Spanish (es)
Inventor
Defne Yarar
Abigail Elizabeth Witt
Jeremiah Dale Farelli
Adam Walter Scheidegger
Jr William Thomas Senapedis
Jodi Michelle Kennedy
Houda Belaghzal
Eugine Lee
Original Assignee
Flagship Pioneering Innovations V Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flagship Pioneering Innovations V Inc filed Critical Flagship Pioneering Innovations V Inc
Publication of MX2023007116A publication Critical patent/MX2023007116A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2023007116A 2020-12-15 2021-12-15 Composiciones y metodos para modular la expresion de myc. MX2023007116A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063125833P 2020-12-15 2020-12-15
US202163137097P 2021-01-13 2021-01-13
US202163212991P 2021-06-21 2021-06-21
US202163281022P 2021-11-18 2021-11-18
PCT/US2021/010059 WO2022132195A2 (en) 2020-12-15 2021-12-15 Compositions and methods for modulation myc expression

Publications (1)

Publication Number Publication Date
MX2023007116A true MX2023007116A (es) 2024-01-08

Family

ID=82060102

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023007116A MX2023007116A (es) 2020-12-15 2021-12-15 Composiciones y metodos para modular la expresion de myc.

Country Status (8)

Country Link
US (1) US20240132559A1 (https=)
EP (1) EP4262849A4 (https=)
JP (1) JP2023553490A (https=)
KR (1) KR20230120138A (https=)
AU (1) AU2021401231A1 (https=)
CA (1) CA3205133A1 (https=)
MX (1) MX2023007116A (https=)
WO (1) WO2022132195A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7682604B2 (ja) 2016-09-07 2025-05-26 フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド 遺伝子発現をモジュレートするための方法および組成物
CN115192714B (zh) * 2022-07-08 2024-09-17 沈阳药科大学 Hdac6抑制剂在制备治疗dnmt3a基因缺失癌症的药物中的用途
TW202417012A (zh) * 2022-08-19 2024-05-01 美商旗艦先鋒創新公司 包含myc調節劑及檢查點抑制劑之組合療法
WO2024238723A1 (en) 2023-05-16 2024-11-21 Omega Therapeutics, Inc. Methods and compositions for modulating pcsk9 expression
WO2024238726A1 (en) 2023-05-16 2024-11-21 Omega Therapeutics, Inc. Methods and compositions for modulating methylation of a target gene
WO2024243438A2 (en) * 2023-05-23 2024-11-28 Omega Therapeutics, Inc. Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression
WO2025019742A1 (en) 2023-07-19 2025-01-23 Omega Therapeutics, Inc. Methods and compositions for modulating ctnnb1 expression
WO2025064469A1 (en) * 2023-09-18 2025-03-27 Omega Therapeutics, Inc. Methods for assessing dosage for epigenetic modifying agents
WO2025144907A1 (en) * 2023-12-27 2025-07-03 Flagship Pioneering Innovations V, Inc. Kinase inhibitors and particles comprising myc modulators

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997011972A1 (en) * 1995-09-28 1997-04-03 The Trustees Of Columbia University In The City Of New York Chimeric dna-binding/dna methyltransferase nucleic acid and polypeptide and uses thereof
GB201119904D0 (en) * 2011-11-17 2011-12-28 Univ Vilnius Analysis of methylation sites
US20170369855A1 (en) * 2014-12-24 2017-12-28 Dana-Farber Cancer Institute, Inc. Systems and methods for genome modification and regulation
KR101900278B1 (ko) * 2016-04-18 2018-09-19 건국대학교 글로컬산학협력단 Myc-ap4 축 활성화된 암의 예방 또는 치료용 조성물의 스크리닝 방법
WO2018111944A1 (en) * 2016-12-12 2018-06-21 Whitehead Institute For Biomedical Research Regulation of transcription through ctcf loop anchors
JP2020515258A (ja) * 2017-03-31 2020-05-28 アジェノビア コーポレーション 抗ウイルス治療剤
US20190233805A1 (en) * 2017-10-04 2019-08-01 The Regents Of The University Of California Targetable proteins for epigenetic modification and methods for use thereof
US20220380760A1 (en) * 2018-10-15 2022-12-01 Flagship Pioneering Innovations V, Inc. Disrupting genomic complex assembly in fusion genes
US11866469B2 (en) * 2019-02-06 2024-01-09 Klogenix Llc DNA binding proteins and uses thereof

Also Published As

Publication number Publication date
EP4262849A2 (en) 2023-10-25
EP4262849A4 (en) 2024-10-30
JP2023553490A (ja) 2023-12-21
KR20230120138A (ko) 2023-08-16
CA3205133A1 (en) 2022-06-23
US20240132559A1 (en) 2024-04-25
WO2022132195A3 (en) 2022-07-28
WO2022132195A8 (en) 2023-06-22
WO2022132195A2 (en) 2022-06-23
AU2021401231A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
MX2023007116A (es) Composiciones y metodos para modular la expresion de myc.
WO2023250427A3 (en) Formulations for modulating myc expression
PH12021552613A1 (en) METHODS AND COMPOSITIONS FOR EDITING RNAs
PH12022551636A1 (en) Anti-cd73 antibodies and uses thereof
PH12021550805A1 (en) Methods and Compositions for Editing RNAs
WO2021158921A3 (en) Adenine base editors and uses thereof
BR112020022722A8 (pt) Genoma e seu uso, vetor, partícula, molécula de ácido nucleico isolada, ácido nucleico, composição, tratamento, método
MX2023006566A (es) Sistemas crispr tipo v clase 2 diseñados por ingeniería.
MX2022011460A (es) Composiciones y métodos para el direccionamiento de c9orf72.
GB2569733A (en) RNA-guided nucleic acid modifying enzymes and methods of use thereof
WO2021034984A3 (en) Skeletal myoblast progenitor cell lineage specification by crispr/cas9-based transcriptional activators
WO2022046804A3 (en) Compositions and methods for assaying proteins and nucleic acids
NZ788988A (en) Conjugates and methods for treating liver fibrosis
MX2022008485A (es) Un metodo para modificar celulas asesinas naturales para dirigirse a tumores positivos a cd70.
BR112017018861A2 (pt) métodos para tratar câncer mantendo perda hemizigótica de tp53
BR112022006476A2 (pt) Oligonucleotídeos com análogos de nucleosídeos
WO2022034374A3 (en) Improved gene editing
WO2023086938A3 (en) Type v nucleases
PH12022552557A1 (en) Aptamers that bind thiamine analogs and derivatives
WO2021026488A3 (en) Use of pcbp1 to generate induced pluripotent stem cells while inhibiting oncogenesis
WO2020242719A3 (en) Inhibitors of rna-binding proteins, compositions thereof, and therapeutic uses thereof
WO2024040229A8 (en) Combination therapies comprising myc modulators and checkpoint inhibitors
WO2022236276A3 (en) Anti-tigit antibodies, anti-cd96 antibodies, and methods of use thereof
MX2025009394A (es) Los patrones de fragmentación de adn libre de células derivados de delfi diferencian subtipos histológicos de cánceres de pulmón de forma no invasiva
WO2023250429A3 (en) Combination therapies comprising myc modulation